HC Wainwright Issues Optimistic Outlook for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at HC Wainwright upped their Q1 2025 EPS estimates for Sarepta Therapeutics in a research report issued on Monday, December 2nd. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of $2.35 for the quarter, up from their previous forecast of $2.32. HC Wainwright currently has a “Sell” rating and a $80.00 price target on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.09 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.64 EPS, Q3 2025 earnings at $2.73 EPS, Q4 2025 earnings at $2.84 EPS and FY2025 earnings at $10.54 EPS.

SRPT has been the subject of a number of other reports. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Robert W. Baird cut their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Needham & Company LLC cut their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research note on Wednesday, November 27th. Finally, Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $175.77.

Sarepta Therapeutics Stock Down 4.0 %

Shares of NASDAQ:SRPT opened at $127.95 on Tuesday. The stock has a market capitalization of $12.22 billion, a price-to-earnings ratio of 102.36 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a 1-year low of $83.97 and a 1-year high of $173.25. The company’s fifty day moving average is $122.50 and its two-hundred day moving average is $131.48.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tidal Investments LLC increased its stake in shares of Sarepta Therapeutics by 91.2% in the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock worth $704,000 after buying an additional 2,688 shares during the period. World Investment Advisors LLC bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $2,418,000. Sunbelt Securities Inc. boosted its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares during the last quarter. Finally, M&T Bank Corp raised its stake in Sarepta Therapeutics by 8.5% in the 3rd quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 349 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.